Dosing Study of Remifentanil for Smooth Removal of the Laryngeal Mask Airway (LMA)
Overview
The investigators attempted to determine the optimal effect-site concentration of remifentanil for smooth removal of the LMA from propofol anesthesia.
Full Title of Study: “Effect-site Concentration of Remifentanil for Smooth Removal of the LMA From Propofol Anesthesia”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: Double (Participant, Investigator)
- Study Primary Completion Date: February 2014
Detailed Description
At the end of the surgery, propofol infusion was stopped and remifentanil was titrated to predetermined (initial concentration 1.0 ng/ml for the first patient). LMA removal was performed when the patients opened their eyes and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed.
Interventions
- Drug: remifentanil
- The concentration of remifentanil was determined by modified Dixon’s up-and-down method, starting from 1.0 ng/ml (0.2 ng/ml as a step size)
- Device: laryngeal mask airway (LMA)
- LMA was removed when the patients opened their eyes, and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed
Arms, Groups and Cohorts
- Experimental: remifentanil
- LMA removal was accomplished when remifentanil was maintained a predetermined concentration throughout the emergence periods.
Clinical Trial Outcome Measures
Primary Measures
- smooth removal of LMA
- Time Frame: from end of surgery to removal of LMA (participants will be followed for the emergence periods, an expected average of 15 min).
- the response of patients to the removal of LMA (classified as either ‘success [smooth emergence]’ or ‘failure’) during infusion of remifentanil.
Participating in This Clinical Trial
Inclusion Criteria
- ASA I-II patients undergoing general anesthesia for short elective surgery (<1 hr) Exclusion Criteria:
- G-E reflux – obesity (BMI>30) – anticipated difficult airway
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 60 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Ajou University School of Medicine
- Provider of Information About this Clinical Study
- Principal Investigator: Jong Yeop Kim, Associate professor – Ajou University School of Medicine
- Overall Official(s)
- Jong Yeop Kim, MD, Study Director, Ajou University School of Medicine
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.